'
The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
Related Resources for this page:
- Biological Pathways
- Therapeutic Targets
- Research Education
- Clinical Trials
- Future Directions
- Antibody-Drug conjugates
- Emerging therapeutic options
- Emerging therapeutic options
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- VEGF, MVD, and metastases in gastric carcinoma
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Emerging therapeutic options
- Emerging therapeutic options
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- VEGF, MVD, and metastases in gastric carcinoma
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Non-Antibody Biologics
- Apoptosis
- VEGF expression in gastric cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- VEGF, MVD, and metastases in gastric carcinoma
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Targeted Small Molecules
- Apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- VEGF expression in gastric cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MAPK Signaling
- Melanoma
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- VEGF, MVD, and metastases in gastric carcinoma
- PI3K/Akt/mTOR Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Traditional Monoclonal Antibodies
- Anti-EGFL7
- B-cell Surface Proteins
- Glossary
- Emerging therapeutic options
- Emerging therapeutic options
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- Melanoma
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- VEGF, MVD, and metastases in gastric carcinoma
- Angiogenic Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Antibody-Drug conjugates
Share
Glioblastoma
Disease Information
Genentech BioOncology is dedicated to advancing the science of glioblastoma therapy through comprehensive research programs and education. Glioblastomas usually form in astrocytes in the cerebral white matter.1
Glioblastoma Demographic Statistics
- In 2004–2007, an estimated 37,890 Americans were diagnosed with glioblastoma—16.7% of all reported brain tumors2
Glioblastoma Epidemiology
- Most brain tumors are not associated with known risk factors.1 However, risk factors include ionizing radiation exposure to the head and a family history of inherited conditions such as neurofibromatosis type 1 and Li-Fraumeni syndrome1,3
- The 5-year survival rate for patients with glioblastoma is 2.9%4
- The median survival time for glioblastoma is limited to approximately 10 to 15 months5
Glioblastoma Symptoms
Symptoms of glioblastoma include headache; nausea; vomiting; blurred vision; balance problems; drowsiness; seizure; hemiparesis; and progressive memory, personality, or neurologic deficits.1,3
Other links to glioblastoma disease information
These links give a sampling of other sites offering information on glioblastoma, which you may find useful in your practice.
- National Cancer Institute at National Institutes of Health, Brain Tumor
- ASCO Cancer Portals - Head & Neck Cancers
- Cancer Facts & Figures
Unless otherwise indicated, Genentech, Inc. is neither affiliated with nor endorses any of the organizations listed.
References:
- 1.
- American Cancer Society. Brain and spinal cord tumors in adults. www.cancer.org/Cancer/BrainCNSTumorsinAdults/DetailedGuide/brain-and-spinal-cord-tumors-in-adults-what-is-cancer. Accessed April 14, 2011.
- 2.
- CBTRUS (2011). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL. Web site: www.cbtrus.org. Accessed April 13, 2011.
- 3.
- US Department of Health and Human Services. National Cancer Institute. What you need to know about™ brain tumors. Accessed April 14, 2011.
- 4.
- Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Cancer of the brain and other central nervous system. In: SEER Survival Monograph. National Cancer Institute. www.seer.cancer.gov/publications/survival/surv_brain.pdf. Accessed April 14, 2011.
- 5.
- Nieder C, Grosu AL, Astner S, Molls M. Treatment of unresectable glioblastoma multiforme. Anticancer Res. 2005;25:4605-4610. PMID: 16334150